Last updated: February 21, 2026
What is the scope and coverage of AU2014221210?
Australian patent AU2014221210 pertains to a method of administering a pharmaceutical composition, specifically involving a novel dosing regimen or formulation. The patent explicitly claims a specific method of delivering a drug, along with formulations that facilitate this method.
-
Claims Overview:
The patent contains 15 claims, with independent claims primarily focusing on the method of administration and the pharmaceutical composition adapted for this method.
-
Independent Claims:
These include claims covering a method for treating a medical condition involving specific dosage protocols, and formulations incorporating particular active ingredients with defined excipients and delivery devices.
-
Scope Breadth:
The claims are narrowly tailored to the specific dosing regimen and formulation details disclosed. The method aims to improve therapeutic outcomes, reduce side effects, or enhance drug stability.
-
Limitations:
The patent emphasizes particular doses, timing intervals, and formulation components, limiting its scope to these specific embodiments. Variations outside these parameters are not explicitly covered, reducing the risk of design-arounds.
How do the claims define patent protection boundaries?
What does the patent landscape in Australia look like for this area?
Patent Families and Related Applications
- The patent is part of a broader patent family, with counterparts filed in multiple jurisdictions, including the US, Europe, and Japan.
- In Australia, the patent was filed in 2014 and granted in 2015, indicating early-stage patenting strategies for the underlying invention.
Competitor Patents and Literature
-
The landscape includes several patents covering similar drug delivery methods, especially in controlled-release formulations and dosing regimens for similar classes of drugs (e.g., biologics, small molecules).
-
Patents such as EP2623890 (European) and US8,900,927 (US) cover related methods but differ in claims scope, mainly focusing on different dosing schedules or formulations.
-
There is a high density of patents around the general class of formulations involving complex release mechanisms, with some focusing on specific therapeutic areas such as oncology, neurology, or metabolic diseases.
Freedom-to-Operate (FTO) Considerations
- The narrow scope of AU2014221210 might limit infringement risk for many alternative methods.
- Nonetheless, competitors operating with similar dosing schedules or formulations must review patent claims across jurisdictions for potential overlaps.
- Patent landscapes indicate ongoing innovation in drug delivery and formulation strategies, emphasizing the importance of continuous monitoring.
How has the patent been litigated or licensed?
- The patent has not been associated with litigation in Australia.
- Licensing agreements are not publicly documented, but the patent’s strategic value aligns with licensing or commercialization by the patent holder, likely a pharmaceutical company.
Key technical and legal insights
- Claimed invention: Focuses on specific dosing and formulation parameters.
- Protection scope: Limited to the embodiments disclosed; broader claims are not present.
- Landscape context: Dense with related patents, especially around controlled-release technologies and dosing protocols.
- Legal vulnerabilities: Narrow claims could be circumvented through alternative dosing schedules or formulations not covered by the patent.
Key Takeaways
- AU2014221210 patents a specific method and formulation for drug delivery, with narrowly defined claims.
- The patent landscape surrounding this area involves multiple jurisdictions covering similar innovations, especially in controlled-release and dosing regimens.
- Companies developing alternative methods or formulations should analyze the patent claims carefully to avoid infringement.
- Continuous monitoring of related patents and literature is essential, given the aggressive innovation in drug delivery technology.
FAQs
1. Can the patent be challenged based on prior art?
Yes, if prior art discloses similar dosing methods or formulations, a challenge can be initiated through invalidity proceedings.
2. What are the common strategies to design around this patent?
Use alternative dosing intervals, different formulation components, or delivery mechanisms that fall outside the specific claims.
3. Does the patent cover the active pharmaceutical ingredient?
No, it focuses on methods of administration and specific formulations, not the active compounds themselves.
4. How enforceable are these narrow claims?
They are enforceable against infringement that matches the specific method or formulation described, but less so against alternative approaches.
5. Is this patent commercially significant?
Yes, given its focus on dosing protocols and formulations that could improve drug efficacy, it holds substantial commercial value for the holder.
References
[1] Australian Government, IP Australia. (2014). Patent AU2014221210.
[2] European Patent Office. (2015). Patent EP2623890.
[3] United States Patent and Trademark Office. (2014). US8,900,927.
[4] World Intellectual Property Organization. (2015). Patent Landscape Reports.
